SGLT2 Inhibitors: Benefit/Risk Balance (Q38931842)

7 September 2017

1 reference

title

SGLT2 Inhibitors: Benefit/Risk Balance (English)

1 reference

7 September 2017

André J Scheen

1

1 reference

7 September 2017

1 October 2016

1 reference

7 September 2017

Current diabetes report

1 reference

7 September 2017

16

1 reference

7 September 2017

92

1 reference

7 September 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-016-0789-4

7 September 2017

0 references

cites work

SGLT inhibitors in management of diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Possible adverse effects of SGLT2 inhibitors on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin: a review of its use in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Weight management in type 2 diabetes: current and emerging approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 inhibitors: their potential reduction in blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Serum uric acid and the risk of cardiovascular and renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of dapagliflozin on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Safety of canagliflozin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

The EMPA-REG study: What has it told us? A diabetologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of SGLT2 inhibitors on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Euglycemic Diabetic Ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

SGLT2 Inhibitors May Predispose to Ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of diabetes drugs on the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0789-4

Heart failure: SGLT2 inhibitors and heart failure -- clinical implications

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27541294

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Review on the Relationship between SGLT2 Inhibitors and Cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27541294

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27541294

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11892-016-0789-4

1 reference

PubMed ID

27541294

Dimensions Publication ID

7 September 2017

0 references

1 reference

PubMed ID

27541294